12 years. $2 billion. That’s what it typically costs to bring one new medicine to the world.

 

I have seen disruptions in Banking, Retail, Media. But healthcare – that 12-year number always seemed like baked into the biology itself, not just the process. Then I came across a news article in Biospace.

 

Generate:Biomedicines just dosed the first patient in a global Phase III trial for GB-0895 — an antibody for severe asthma that their AI platform designed from scratch. So, from Concept to Phase III, in five years.

 

Not 12. Five. Wow.

 

Let me be clear about what this actually is. Not a press release. Not about the company getting listed recently. Not a pilot. A 1,600-patient trial running across multiple countries, for a complex antibody that no AI system had ever gotten this far before. Their platform was running optimisation cycles in weeks. The same work used to take years of lab iterations, failed experiments, and dead ends.

 

The CEO, Mike Nally, said the long lead times in drug development are hiding what’s actually the real promise of these technologies. That’s a quiet, important observation. Because while everyone is arguing about whether AI is overhyped, a team of scientists just compressed a 12-year journey into five — and it barely made the news. Should have gotten more attention.

 

They’re not alone, though. Biological Engineering is coming to its own with ML. Eli Lilly partnered with Chai Discovery to design novel biologics. Bayer is working with Cradle on their antibody pipeline. Isomorphic Labs, spun out of Google DeepMind, is partnering with Lilly and Novartis on a combined $1.7 billion in milestone potential. Something has shifted. Pharma spent years talking about AI. 2026 is when what they are building is coming across, with IPO Markets giving them attention.

 

Think about what it actually means for a patient.

 

Someone with severe asthma waiting on a new treatment. Someone with COPD whose current options aren’t working. Every year cut from the development timeline is a year they don’t have to wait. That’s not an abstraction. That’s a real person’s life getting better.

 

The hardest part is never the tech itself. It’s getting people to believe the technology is actually real — not just a demo, not just a pilot, but something that works at scale in the messy real world.

 

Generate:Biomedicines just made it real. Check out their pipeline at https://lnkd.in/gK5dd2h7

 

Sources: BioSpace (March 2, 2026), Genetic Engineering & Biotechnology News (March 9, 2026), BioWorld (March 2026)

Shailendra Gupta
(Co-Founder and CEO of Mind IT Systems)

 

Shailendra is Co-Founder and CEO of Mind IT Systems and is responsible for strategy and business relations.

With around two decades of experience in getting things done in marketing, sales, strategy, delivery, or technology, he has a successful track record of leading startups and mid-size companies and being a prime contributor to stakeholder management, growth, and value creation. A thought leader in the geo-social space, he is highly respected for realizing new paradigms in marketing, solutions, and approaches.